DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...

The first-of-its-kind facility in India has received an investment of $75 million from the company to build it vertically ...

ViroCell Biologics ("ViroCell" or the "Company"), a cell and gene therapy ("CGT") contract development and manufacturing organization ("CDMO") specializing in GMP viral vector manufacturing for ...

With a storied history in vaccine development, India's Bharat Biotech is shaking things up and answering the call of advanced ...

Scientists from Juntendo University and The University of Tokyo have created an adeno-associated virus (AAV)-based genome ...

Creative Diagnostics, a global provider of reagents and analytical services, has released its innovative Gene Copy Number ...

A new study in the peer-reviewed journal Human Gene Therapy indicates that DNA impurities derived from plasmid and host cell ...

MeiraGTx's innovative gene therapies for ocular diseases & more are backed by strong clinical data and funding. Click here to find out why MGTX stock is a Buy.

Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death of a patient taking Sarepta’s Elevidys raises important safety questions.